Skip to main content

MINI REVIEW article

Front. Cardiovasc. Med.
Sec. General Cardiovascular Medicine
Volume 11 - 2024 | doi: 10.3389/fcvm.2024.1350573
This article is part of the Research Topic Insights in Cardiology from Caring for a Diverse Community: Perspectives from Inova Schar Heart and Vascular View all 22 articles

Preclinical Screening for Cardiovascular Disease with High-Sensitive Cardiac Troponins: Ready, Set, Go?

Provisionally accepted
Aya Awwad Aya Awwad 1Yashika Parashar Yashika Parashar 1Soahum Bagchi Soahum Bagchi 1Saman A. Siddiqui Saman A. Siddiqui 1Ogheneochuko Ajari Ogheneochuko Ajari 1Christopher DeFilippi Christopher DeFilippi 2*
  • 1 Harvard Medical School, Boston, Massachusetts, United States
  • 2 Inova Health System, Falls Church, United States

The final, formatted version of the article will be published soon.

    Cardiovascular disease (CVD), including atherosclerosis, valvular etiologies, or myocardial disorders is typically asymptomatic for years, representing an occult phase of illness. Readily available preventive treatments to reduce cholesterol and blood pressure among other risk factors have the potential to reduce and delay incident myocardial infarction (MI), heart failure (HF) and cardiovascular (CV) deaths.Measurement of circulating levels of cardiac troponin T (cTnT) and troponin I (cTnI) released from cardiomyocytes, as the result of injury, have been the biochemical standard for the diagnosis of MI for more than 20 years. The recent adoption of high-sensitivity (hs) assays, which are capable of measuring cTnT and I levels in more than 50% of the general population, has revealed a clear association between progressively higher biomarker levels and future CV events. cTn levels measured by hs assays have also demonstrated correlations between elevated biomarker levels and occult CVD such as coronary artery disease and myocardial fibrosis in cross-sectional imaging studies. In this review, we provide evidence to consider measuring hs-cTnT and hs-cTnI to screen for patient CV risk and provide an example of a scenario in which such screening may improve outcomes through decision support for aggressive management of blood pressure.

    Keywords: Troponin, biomarker, screening, risk, prevention

    Received: 05 Dec 2023; Accepted: 30 Sep 2024.

    Copyright: © 2024 Awwad, Parashar, Bagchi, Siddiqui, Ajari and DeFilippi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Christopher DeFilippi, Inova Health System, Falls Church, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.